Regeneron Pharmaceuticals, Inc.
NASDAQRegeneron Pharmaceuticals has rallied sharply into its July 29 earnings date, yet the Street's response has been to lower price targets rather than raise them — a divergence that frames the week's most interesting tension. Options traders have shifted notably more bullish over the past six weeks. The put/call ratio has dropped to 0.77, well below its 20-day average of 0.83 and…
Snapshot as of 18 Aug 2026
Regeneron Pharmaceuticals has rallied sharply into its July 29 earnings date, yet the Street's response has been to lower price targets rather than raise them — a divergence that frames the week's most interesting…
Regeneron Pharmaceuticals enters the back half of June with an unusual split: options traders are rotating away from defensive positioning just as short sellers add exposure for the first time in weeks. The clearest…
Regeneron Pharmaceuticals heads into its June 12 earnings report with analysts cutting price targets across the board and the stock nursing a 14% loss over the past month. The analyst picture is the clearest signal of…
Regeneron reports Tuesday with short interest edging lower and analysts raising price targets. Put-call ratio signals moderating hedging demand versus recent weeks. Short interest in REGN stood at 2.48 million shares…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for REGN — free to start on ORTEX.
Sign up for free →Open REGN on ORTEX